scholarly journals Driving Behaviour in Depression: Findings from a Driving Simulator Study

Safety ◽  
2019 ◽  
Vol 5 (4) ◽  
pp. 70
Author(s):  
Vagioula Tsoutsi ◽  
Dimitris Dikeos ◽  
Maria Basta ◽  
Maria Papadakaki
Keyword(s):  
Sleep Disturbance ◽  
Sleep Disturbances ◽  
Driving Simulator ◽  
Executive Dysfunction ◽  
Lateral Position ◽  
Driving Ability ◽  
Aggressive Driving ◽  
The Road ◽  
Driving Behaviour ◽  
Preceding Vehicle

Depression is characterized by mental, emotional and executive dysfunction. Among its symptoms, sleep disturbance and anxiety are very common. The effects of depression and its treatment may have an impact on driving behaviour. In order to evaluate driving performance in depression, 13 patients and 18 healthy controls completed questionnaires and scales and were tested in a driving simulator. Driving simulator data included lateral position (LP), speed and distance from the preceding vehicle. History of collisions was associated with depression, body mass index (BMI) and next-day consequences of sleep disturbance. Aggressive driving was associated with fatigue and sleep disturbances. Concerning driving simulator data, a reduced ability to maintain constant vehicle velocity was positively correlated to BMI and insomnia. An LP towards the middle of the road was associated with anxiety. On the other hand, an LP towards the shoulder was associated with depression and next-day consequences of sleep disturbance, while a positive correlation was found between distance from the preceding vehicle and use of drugs with potential hypnotic effects; both these findings show that patients suffering from depression seem to realize the effects of certain symptoms on their driving ability and thus drive in a more defensive way than controls.

scholarly journals CROSS-STUDY RESEARCH ON UTILITY AND VALIDITY OF DRIVING SIMULATOR FOR DRIVER BEHAVIOR ANALYSIS

2017 ◽  
Vol 12 ◽  
pp. 68 ◽  
Author(s):  
Michal Matowicki ◽  
Ondřej Přibyl
Keyword(s):  
Traffic Safety ◽  
Driving Simulator ◽  
Driver Behavior ◽  
Full Range ◽  
Experimental Studies ◽  
Cost Effective ◽  
Lateral Position ◽  
Driving Behaviour ◽  
Experience Levels ◽  
Wide Range

Driving is one of the most ordinary and universal everyday tasks and, at the same time, one of the most complex and dangerous. It requires a full range of sensory, perceptual, cognitive, and motor functions, all of which can be affected by a wide range of stressors and experience levels. Therefore, exploring of human behaviour while controlling a vehicle is a crucial task in improving traffic safety. Experimental studies can always be conducted with on-road tests, however, using a simulator is safer and more cost-effective. The main goal of this paper is to demonstrate if and under what conditions could a driving simulator provide sufficient results required for a proper study of driver behavior. It discusses its limits and advantages. Overall, the research reviewed in this paper indicates that simulator driving behaviour approximates (relative validity of speed and lateral position of vehicle on road), but does not exactly replicate (absolute validity), on-road driving behaviour.

scholarly journals Aggressive Driving Behaviours in Cannabis Users. The Influence of Consumer Characteristics

2021 ◽  
Vol 18 (8) ◽  
pp. 3911
Author(s):  
Sonia Ortiz-Peregrina ◽  
Carolina Ortiz ◽  
Rosario G. Anera
Keyword(s):  
Visual Function ◽  
Driving Simulator ◽  
Sociodemographic Factors ◽  
Aggressive Driving ◽  
Significant Deterioration ◽  
Information Campaigns ◽  
Driving Behaviour ◽  
Dangerous Driving ◽  
Speed Management ◽  
Reported Data

This study analysed dangerous driving behaviours in twenty young occasional cannabis users through objective and self-reported data, studying the relationship between the two aspects. Visual function was assessed in a baseline session and after smoking cannabis, as well as speed-related behaviour in a driving simulator. The participants responded to questionnaires on sociodemographic factors, their consumption profile, and the incidence of dangerous behaviours (Dula Dangerous Driving Index; DDDI). After cannabis use, the results revealed a significant deterioration in visual function. In terms of speed management, they showed significantly greater acceleration force in the two different sections of the route, and they drove significantly faster. Our correlations indicate that males and heavier users display more risky speed management. Likewise, the heavier cannabis users admitted to increased dangerous driving behaviour, and an accident in the preceding year was associated with a trend towards aggressive driving behaviour according to the DDDI questionnaire. The findings of this study suggest that cannabis users adopt dangerous behaviours when driving, despite the effect this drug has on certain important functions, such as vision. The results suggest a need for awareness-raising and information campaigns.

scholarly journals Factors of the “Aggressive Driving” Behaviour amongst Malaysian Drivers

2019 ◽  
Vol 8 (6) ◽  
pp. 3359-3366
Keyword(s):  
Motor Vehicle ◽  
Anger Expression ◽  
Driving Behavior ◽  
Motor Vehicle Crash ◽  
Aggressive Driving ◽  
The Road ◽  
Driving Anger ◽  
Multiple Factors ◽  
Driving Behaviour ◽  
On The Road

This study explores factors that lead towards aggressive driving behaviour among Malaysian drivers and to determine the highest factor that contributes to these aggressive driving styles in Malaysia. Driving aggressively increases the chances of drivers becoming involved in a motor vehicle crash, and aggressive driving behavior occurs happens due to multiple factors. The Driving Anger Expression Inventory (DAX) is used to calculate the factors corresponding to their anger while driving. There are four factors that has been identified to define how people expressed their anger while driving by using DAX, they are Verbally Aggressive Expression (α=0.7332), Physically Aggressive Expression (α=0.8548), Using the Vehicle for Aggressive Expression (α=0.7267) and Adaptive/Constructive Expression (α=0.8711). At the end of this research, we found out that the Adaptive/Constructive Expression is the highest factor and most commonly used amongst drivers to adapt to these aggressive situations on the road. Followed by the factor Verbally Aggressive Expression and Using the Vehicle for Aggressive Expression. Then, the least often used factor in Malaysia is Physically Aggressive Expression. Therefore, some mitigation plans should be considered towards reducing accidents in Malaysia which is on a yearly rising trend.

scholarly journals Interactions between sleep disturbances and Alzheimer’s disease on brain function: a preliminary study combining the static and dynamic functional MRI

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kaicheng Li ◽  
Xiao Luo ◽  
Qingze Zeng ◽  
Yerfan Jiaerken ◽  
Shuyue Wang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Sleep Disturbance ◽  
Brain Function ◽  
Sleep Disturbances ◽  
Brain Activity ◽  
Vascular Risk Factor ◽  
Underlying Mechanism ◽  
Amyloid Pet

AbstractThough sleep disturbance constitutes the risk factor for Alzheimer’s disease (AD), the underlying mechanism is still unclear. This study aims to explore the interaction between sleep disturbances and AD on brain function. We included 192 normal controls, 111 mild cognitive impairment (MCI), and 30 AD patients, with either poor or normal sleep (PS, NS, respectively). To explore the strength and stability of brain activity, we used static amplitude of low-frequency fluctuation (sALFF) and dynamic ALFF (dALFF) variance. Further, we examined white matter hyperintensities (WMH) and amyloid PET deposition, representing the vascular risk factor and AD-related hallmark, respectively. We observed that sleep disturbance significantly interacted with disease severity, exposing distinct effects on sALFF and dALFF variance. Interestingly, PS groups showed the dALFF variance trajectory of initially increased, then decreased and finally increased along the AD spectrum, while showing the opposite trajectory of sALFF. Further correlation analysis showed that the WMH burden correlates with dALFF variance in PS groups. Conclusively, our study suggested that sleep disturbance interacts with AD severity, expressing as effects of compensatory in MCI and de-compensatory in AD, respectively. Further, vascular impairment might act as important pathogenesis underlying the interaction effect between sleep and AD.

341 Acute effects of seltorexant, a selective orexin-2 antagonist (JNJ- 42847922), on driving after bedtime administration

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A136-A136
Author(s):  
S Brooks ◽  
R G J A Zuiker ◽  
G E Jacobs ◽  
I Kezic ◽  
A Savitz ◽  
...  
Keyword(s):  
Postural Stability ◽  
Driving Simulator ◽  
Motor Vehicle ◽  
Subjective Effects ◽  
Driving Ability ◽  
Post Dose ◽  
Double Blind ◽  
Increased Risk ◽  
Subjective Sleepiness ◽  
The Difference

Abstract Introduction Seltorexant (JNJ-42847922), a potent and selective antagonist of the human orexin-2 receptor, is being developed for the treatment of major depressive disorder. Seltorexant also has sleep-promoting properties. Investigating the effects of sleep-promoting medications on driving is important because some of these agents (e.g. GABAA receptor agonists) may be associated with increased risk of motor vehicle accidents. We evaluated the effect of seltorexant on driving after forced awakening at night, using a validated driving simulator. Methods This double-blind, placebo and active-controlled, randomized, 3-way cross-over study was conducted in 18 male and 18 female healthy subjects. All subjects received seltorexant 40 mg, zolpidem 10 mg, or placebo 15 minutes before bedtime. Eighteen subjects were awakened at 2- and 6-hours post-dose, and the other 18 at 4- and 8-hours post-dose. At those timepoints, pharmacokinetics, objective (standard deviation of the lateral position [SDLP]) and subjective effects (using Perceived Driving Quality and Effort Scales) on driving ability, postural stability and subjective sleepiness were assessed. Results For seltorexant, the SDLP difference from placebo (95% confidence interval) at 2-, 4-, 6- and 8-hours post-dose was 3.9 cm (1.26, 6.60), 0.9 cm (-1.08, 2.92), 1.1 cm (-0.42, 2.63), and 0.6 cm (-2.75, 1.55), respectively vs. 9.6 cm (6.97, 12.38), 6.6 cm (3.53, 9.60), 4.7 cm (1.46, 7.85), and 1.3cm (-1.16, 3.80), respectively for zolpidem. The difference from placebo was significant at 2-hours after taking seltorexant, while the difference from placebo was significant at 2, 4 and 6-hours after zolpidem. Subjective driving quality was decreased for both drugs at all time points and driving effort was increased up to 4-hours post-dose for both medications. Subjective sleepiness showed a significant increase compared to placebo 2- and 4-hours after administration of either drug. Postural stability was decreased up to 2-hours after administration of seltorexant, and up to 4-hours after administration of zolpidem. Conclusion Compared to zolpidem, objective effects on driving performance were more transient after seltorexant administration and largely normalized by 4–6 hours post-dose. Support (if any) This work was sponsored by Janssen R&D.

631 Sleep SMART in Adolescents with Neurodevelopmental Disorders

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A247-A248
Author(s):  
Alyson Hanish ◽  
Abbey Jo Klein ◽  
Therese Mathews ◽  
Ann Berger ◽  
Kevin Kupzyk ◽  
...  
Keyword(s):  
Sleep Disturbance ◽  
Neurodevelopmental Disorders ◽  
Sleep Disturbances ◽  
Immediate Release ◽  
Sleep Time ◽  
Normative Values ◽  
Exogenous Melatonin ◽  
Contingency Contracting ◽  
Sleep Questionnaires ◽  
The Impact

Abstract Introduction: Introduction Sleep disturbances are common in adolescents with neurodevelopmental disorders (NDDs). Inclusion of vulnerable populations such as adolescents with NDDs into sleep intervention efforts is essential as they are at high-risk for poor physical/mental health outcomes. The objective of this study is to pilot a sequential, multiple assignment, randomized trial (SMART) design to compare the impact of a sequence of sleep interventions, based on treatment response, to optimize sleep health in adolescents with NDDs. Methods: Methods Recruitment began June 2019 using convenience sampling. The SMART pilot feasibility study includes 1-week of baseline sleep data, and two 4-week periods of a sleep intervention (9-week total study enrollment). Interventions include exogenous melatonin, The Bedtime Bank, and their combination. Exogenous melatonin (liquid, immediate release, 3mg) is administered 30 minutes before bedtime. The Bedtime Bank, a behavioral sleep intervention, is based upon contingency contracting that relies on a credit- or debt-based system to hold adolescents accountable for maintaining a consistent bedtime. At baseline participants completed demographics, PROMIS pediatric sleep questionnaires, the Cleveland Adolescent Sleepiness Questionnaire (CASQ), salivary & urinary endogenous melatonin measurement, and one week of actigraphy. Upon enrollment, participants were randomly assigned to either melatonin or The Bedtime Bank. Participants who respond (nightly increase in total sleep time (TST) ≥18 minutes) remain on the assigned intervention; if non-responsive participants are re-randomized to a different sleep intervention or combination. Results: Results At baseline, participants (n=29, aged 10–18 years) had an average TST of 7 hours 11 minutes. PROMIS Sleep Disturbance (M=64.3, SE=2.5), PROMIS Sleep-Related Impairment scores (M=58.9, SE=2.2), and CASQ scores (M=40.0, SD= 10.5) were higher than reported normative values. Salivary DLMO & urinary 6-sulfatoyxmelatonin analysis is ongoing. For participants who completed the full 9-week trial, nearly 30% (n=7/24) were responsive (increased baseline TST ≥18 minutes) to one of the 4-week interventions. Conclusion: Conclusion Baseline data of the enrolled participants demonstrates poor indicators of TST, sleep disturbance, and sleep related impairment. Preliminary results of this SMART indicate some adolescents are responsive to sleep interventions aimed to improve their TST. Support (if any) Support: This clinical trial is funded by the National Institute of Nursing Research, National Institutes of Health (1K01NR017465-01A1).

scholarly journals Selected CNS Outcomes Among INSTI Antiretrovirals

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S39-S39 ◽  
Author(s):  
David Wohl ◽  
Anthony Mills ◽  
Robertino Mera ◽  
David Piontkowsky
Keyword(s):  
Sleep Disturbance ◽  
Mixed Models ◽  
Sleep Disturbances ◽  
Integrase Inhibitors ◽  
Healthcare Database ◽  
Medical Claims ◽  
Significant Difference ◽  
Rate Ratios ◽  
Blinded Trial ◽  
Research Grant

Abstract Background Higher rates of neuropsychiatric events among patients on dolutegravir (DTG) compared with other integrase inhibitors (INSTIs) have been reported from clinic cohorts and one blinded trial. We compared select neurological and psychiatric events in a large sample of patients treated with different INSTIs. Methods The Quintiles IMS database, which includes pharmacy and medical claims records, was examined for HIV infected patients treated from 2006 to 2016 with DTG (TIVICAY/TRIUMEQ), elvitegravir (EVG, STRIBILD), or raltegravir (RAL, ISENTRESS). The dependent variable outcomes were insomnia/sleep disturbance and depression. A propensity score was created to adjust for variables associated with treatment with a particular INSTI including age, gender, year of initial INSTI exposure, and enrollment time. Multivariate Poisson mixed models were used to generate incidence rate ratios (IRRs). Results Records for 54,151 distinct HIV-infected patients treated with DTG, EVG, or RAL were identified. In the multivariate model the rate of insomnia/sleep disturbance events was significantly higher for patients treated with DTG vs. EVG (IRR 1.21 [95% CI 1.09–1.33, P < 0.001]), but was not significantly different when comparing DTG to RAL (IRR 1.04 [95% CI 0.94–1.14, P = 0.459]). Likewise, the rate of incident depression was significantly higher for patients treated with DTG vs. EVG (IRR 1.18 [95% CI 1.09–1.27, P < 0.001], but not when comparing DTG to RAL (IRR 0.93 [95% CI 0.87 – 1.01, P = 0.068]). Conclusion In this analysis using a large healthcare database, significantly higher adjusted rates of both incident insomnia/sleep disturbances (21% more) and depression (18% more) were found among patients treated with DTG compared with EVG. In contrast, a significant difference in the rates of either outcome was not observed when comparing DTG and RAL. Further studies are warranted to determine the risk of neuropsychiatric events in patients treated with different INSTIs. Disclosures D. Wohl, Gilead Sciences: Consultant and Investigator, Consulting fee and Research grant; Viiv: Consultant and Investigator, Consulting fee and Research grant; Janssen: Consultant, Consulting fee; Bristol-Myers Squibb: Consultant, Consulting fee; A. Mills, Gilead Sciences: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Viiv: Consultant and Investigator, Consulting fee and Research grant; Merck: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Janssen: Investigator, Research grant; Bristol-Myers Squibb: Investigator, Research grant; Sangamo Bio Sciences: Investigator, Research grant; R. Mera, Gilead Sciences: Employee and Shareholder, Salary; D. Piontkowsky, Gilead Sciences: Employee and Shareholder, Salary

Sign in / Sign up

Export Citation Format

Share Document